Bladder Cancer

Treatment with induction UGN-101 produced durable responses in patients with low-grade upper tract urothelial carcinoma.

Patients with BCG-unresponsive non-muscle invasive bladder cancer may benefit from treatment with avelumab and BCG induction therapy

In patients with bacillus Calmette-Guérun–unresponsive non-muscle invasive bladder cancer who are being treated with nadofaragene firadenovec, elevated levels of antibody titers may be able to predict efficacy.

Patients with Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer experienced a disease-free survival benefit when treated with intravesical Bacillus Calmette-Guerin and a novel IL-15 superagonist complex .

Patients with Bacillus-Calmette Guérin–unresponsive non–muscle invasive bladder cancer experienced promising responses to treatment with of durvalumab and Vicineum, which was also well tolerated.

Patients with metastatic urothelial carcinoma did not derive further benefit from the addition of berzosertib to cisplatin and gemcitabine.

Patients with muscle-invasive bladder cancer treated with gemcitabine and split-dose cisplatin plus pembrolizumab experienced improved pathological downstaging.

Patients with low-grade upper tract urothelial carcinoma achieved a long period of durable response after undergoing treatment with UGN-101.

Erdafitinib plus cetrelimab displayed strong responses for patients with metastatic or locally advanced urothelial carcinoma.

The FDA has approved nivolumab for patients with high-risk urothelial carcinoma regardless of previous treatment with neoadjuvant chemotherapy, nodal involvement, or PD-L1 status.

Patients with muscle invasive urothelial carcinoma who received adjuvant nivolumab experienced a longer disease-free survival compared with those who received placebo.

Novel eganelisib shows survival-extending potential in patients with triple-negative breast and bladder cancers.

Robert A. Figlin, MD, discusses the potential role of adjuvant immunotherapy for patients with bladder cancer.

Until 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been limited to cisplatin-based regimens and taxanes. This article explores the current and future outlooks for combination therapy with IOs in urothelial carcinoma.

CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to discuss his thoughts on research he believes has the greatest potential to impact standard of care treatment of bladder cancer.

As a bladder-sparing treatment strategy, transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise for patients with muscle-invasive bladder cancer.

CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to talk about data from a phase 2 trial examining the use of neoadjuvant nivolumab plus gemcitabine/cisplatin prior to bladder-sparing surgery.

Regardless of primary tumor site or disease stage, avelumab maintenance was able to elicit overall survival benefit versus best supportive care for platinum-treated urothelial cancer.

Vikram Narayan, MD, details the little-known fact that tobacco cessation is a leading preventative strategy of bladder cancer recurrence.

Vikram Narayan, MD, expanded on his data regarding nadofaragene and NMIBC published at this year’s SUO Meeting.

Narayan expanded on the other studies he contributed to from SUO investigating nadofaragene for patients with NMIBC.

At the 2020 SUO Meeting, Vikram M. Narayan, MD, spoke about the preliminary finds of his work with nadofaragene firadenovec.

Narayan discusses what he thinks the future of nadofaragene firadenovec and bladder cancer are at this year’s SUO Meeting.

Patients who underwent pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.

Data for a key study secondary outcome measure showed that 56.1% of patients who achieved a complete response to Jelmyto maintained that response at 12 months.

“Providers should consider using BLC for surveillance of high-risk NMIBC patients undergoing BCG as it could change clinical management by identifying patients who are BCG unresponsive and eligible for alternative therapy and clinical trials,” said Meera Chappidi, MD.

The efficacy of the novel intravesical gene-mediated therapy nadofaragene firadenovec was sustained across subgroups of patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer.

This study found that radiation therapy may provide some benefit for patients with high-risk non–muscle invasive bladder cancer, though the quality of evidence in this current setting is low.

Research suggested oncologists may recommend specific timeframes in which cystectomy should be performed to avoid unnecessary mortality due to delays.

Researchers sought to better understand the impact of treatment on intimate relationships for patients with bladder cancer.